HU228956B1 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors - Google Patents

Phenyl-piperazine derivatives as serotonin reuptake inhibitors Download PDF

Info

Publication number
HU228956B1
HU228956B1 HU0402313A HUP0402313A HU228956B1 HU 228956 B1 HU228956 B1 HU 228956B1 HU 0402313 A HU0402313 A HU 0402313A HU P0402313 A HUP0402313 A HU P0402313A HU 228956 B1 HU228956 B1 HU 228956B1
Authority
HU
Hungary
Prior art keywords
group
alkyl
carbon atoms
vsgy
compounds
Prior art date
Application number
HU0402313A
Other languages
English (en)
Hungarian (hu)
Inventor
Thomas Ruhland
Garrick Paul Smith
Benny Bang-Andersen
Ask Pueschl
Ejner Knud Moltzen
Kim Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU228956(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HUP0402313A2 publication Critical patent/HUP0402313A2/hu
Publication of HUP0402313A3 publication Critical patent/HUP0402313A3/hu
Publication of HU228956B1 publication Critical patent/HU228956B1/hu
Priority to HUS1400012C priority Critical patent/HUS1400012I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HU0402313A 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors HU228956B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS1400012C HUS1400012I1 (hu) 2001-10-04 2014-03-12 Szerotonin újrafelvételt gátló fenilpiperazin-származékok

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (3)

Publication Number Publication Date
HUP0402313A2 HUP0402313A2 (hu) 2005-02-28
HUP0402313A3 HUP0402313A3 (en) 2010-03-29
HU228956B1 true HU228956B1 (en) 2013-07-29

Family

ID=8160750

Family Applications (3)

Application Number Title Priority Date Filing Date
HU0402313A HU228956B1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
HU1300028A HU230189B1 (hu) 2001-10-04 2002-10-02 Szerotonin újrafelvételt gátló fenilpiperazin-származékok
HUS1400012C HUS1400012I1 (hu) 2001-10-04 2014-03-12 Szerotonin újrafelvételt gátló fenilpiperazin-származékok

Family Applications After (2)

Application Number Title Priority Date Filing Date
HU1300028A HU230189B1 (hu) 2001-10-04 2002-10-02 Szerotonin újrafelvételt gátló fenilpiperazin-származékok
HUS1400012C HUS1400012I1 (hu) 2001-10-04 2014-03-12 Szerotonin újrafelvételt gátló fenilpiperazin-származékok

Country Status (38)

Country Link
US (10) US7144884B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1749818B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP3896116B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100842702B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1319958C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR036659A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE386730T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2002333220C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C036I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BRPI0212733B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2462110C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5580746A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1107924T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE60225162T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1749818T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA007537B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG25095A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2298425T7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0033I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20040220A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HU228956B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL160655A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (2) IS2578B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1436271I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92397I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME00039B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04002959A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY140950A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300652I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO326443B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ531556A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL209253B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1436271E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS52865B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1436271T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (2) UA81749C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003029232A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200401583B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
CN1767829A (zh) * 2003-04-04 2006-05-03 H.隆德贝克有限公司 作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物
WO2004087156A1 (en) * 2003-04-04 2004-10-14 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
ZA200507181B (en) * 2003-04-04 2007-03-28 Lundbeck & Co As 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
DE602004013314T2 (de) * 2003-04-04 2008-08-07 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6-tetrahydropyridin-derivate als serotonin-wiederaufnahme-hemmer
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
WO2005061455A1 (en) 2003-12-23 2005-07-07 H. Lundbeck A/S 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7923444B2 (en) * 2005-02-10 2011-04-12 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PT2044020E (pt) * 2006-06-16 2011-05-12 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfanil)- fenil] piperidina com inibi??o de reabsor??o combinada de serotonina e norepinefrina para o tratamento da dor neurop?tica
ES2361949T3 (es) * 2006-06-16 2011-06-24 H. Lundbeck A/S Formas cristalinas de 4-[2-(4-metilfenilsulfanil)-fenil]piperidina con inhibición de la reabsorción de serotonina y norepinefrina combinada para el tratamiento del dolor neuropático.
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
WO2008151632A1 (en) 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
US8304433B2 (en) 2008-11-14 2012-11-06 Theravance, Inc. Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
WO2010121621A1 (en) 2009-04-24 2010-10-28 H. Lundbeck A/S Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
HRP20130819T1 (en) 2009-08-24 2013-09-30 H. Lundbeck A/S New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
RU2553453C2 (ru) * 2009-10-30 2015-06-20 Янссен Фармацевтика Нв 4-замещенные-2-феноксифениламиновые модуляторы дельта-опиоидных рецепторов
EP2523945A1 (en) * 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
SG185081A1 (en) * 2010-04-30 2012-12-28 Takeda Pharmaceutical Enteric tablet
CA2797809A1 (en) * 2010-04-30 2011-11-03 Takeda Pharmaceutical Company Limited Enteric tablet
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
RS55304B1 (sr) 2011-06-20 2017-03-31 H Lundbeck As Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
CA2855640C (en) 2011-11-14 2020-03-10 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
US9133144B2 (en) 2012-01-03 2015-09-15 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
US9499504B2 (en) 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
UA114016C2 (xx) 2012-12-13 2017-04-10 Композиції, що містять вортіоксетин та донепезил
UA116236C2 (uk) * 2013-02-22 2018-02-26 Х. Луннбек А/С Спосіб одержання вортіоксетину
SI2981520T1 (sl) * 2013-04-04 2019-07-31 Lek Pharmaceuticals D.D. Novi proces za sintezo 1-(2-((2,4-dimetilfenil)tio)fenil)piperazina
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
IN2013MU03121A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
KR20160093025A (ko) 2013-12-20 2016-08-05 하. 룬트벡 아크티에 셀스카브 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
EP3262031A1 (en) 2015-02-25 2018-01-03 Lupin Limited Process for the preparation of vortioxetine
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CN108348486A (zh) * 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
WO2017029377A1 (en) * 2015-08-19 2017-02-23 Amneal Pharmaceuticals Company Gmbh Process for preparation of vortioxetine hydrobromide
WO2017063771A1 (en) * 2015-10-14 2017-04-20 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
CA3030054A1 (en) * 2016-07-15 2018-01-18 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
EA201990362A1 (ru) * 2016-07-22 2019-07-31 Цзянсу Нхвалокан Фармасьютикал Рисерч Энд Дивелопмент Ко., Лтд. Аналог вортиоксетина и его применение и получение
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
EP3582759A4 (en) 2017-02-17 2021-01-06 Unichem Laboratories Ltd BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF VORTIOXETINE BROMHYDRATE
US10836730B2 (en) 2017-02-23 2020-11-17 Unichem Laboratories Ltd. Process for preparation and purification of vortioxetine hydrobromide
MA49056A (fr) * 2017-04-25 2020-03-04 H Lundbeck As Procédé de fabrication de la forme alpha de vortioxétine hbr
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
JP7389761B2 (ja) 2018-06-20 2023-11-30 バイオ アーゲー ファーマシューティカルズ エス．エー． ボルチオキセチンおよびボルチオキセチン中間体を調製するためのワンポット有機擬触媒ｃ－ｈ活性化手法
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF A SPECIFIC SEROTONIN REUPSORPTION INHIBITOR AND A SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
AU2021246973A1 (en) 2020-04-03 2022-11-03 H. Lundbeck A/S 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting
US12281088B2 (en) 2020-09-10 2025-04-22 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Process for the synthesis of vortioxetine
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151752B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-04-13 1973-11-19
CS151751B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-04-13 1973-11-19
CS151753B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-04-13 1973-11-19
CS151755B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) * 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
US6048876A (en) 1995-01-23 2000-04-11 Suntory Limited Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2230209T3 (es) * 1997-10-31 2005-05-01 Daiichi Suntory Pharma Co., Ltd. Procedimiento para preparar n-((4-fenil)metilfenil)piperazinas.
NZ515238A (en) 1999-04-02 2005-02-25 Icos Corp Inhibitors of LFA-1 binding to ICAMs and uses thereof
WO2001010842A2 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
EP1220780A4 (en) * 1999-09-14 2004-03-24 Pharmacopeia Inc ARTICLE COMPRISING A DISPENSING HEAD COMPRISING MULTIPLE CHANNELS
AU2152101A (en) * 1999-12-30 2001-07-16 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
EP1246819A1 (en) 1999-12-30 2002-10-09 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
WO2002059117A1 (en) * 2001-01-23 2002-08-01 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1458689B1 (en) * 2001-12-20 2007-04-11 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004087156A1 (en) * 2003-04-04 2004-10-14 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja

Also Published As

Publication number Publication date
AU2006215994A2 (en) 2006-10-05
DE60233608D1 (de) 2009-10-15
CO5580746A2 (es) 2005-11-30
BR0212733A (pt) 2004-11-16
RS20120158A3 (en) 2013-10-31
KR20060118020A (ko) 2006-11-17
US8476279B2 (en) 2013-07-02
NO2014011I1 (no) 2014-05-13
UA81749C2 (uk) 2008-02-11
KR100770194B1 (ko) 2007-10-25
ES2298425T7 (es) 2022-06-27
US20110009423A1 (en) 2011-01-13
US20160137620A1 (en) 2016-05-19
PT1749818E (pt) 2009-10-06
US10844029B2 (en) 2020-11-24
NL300652I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-01-18
AU2006215994A9 (en) 2006-10-05
NO332355B1 (no) 2012-09-03
CY2014022I1 (el) 2015-12-09
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
EG25095A (en) 2011-08-17
RS52865B (en) 2013-12-31
ES2328725T3 (es) 2009-11-17
DK1436271T3 (da) 2008-06-09
CA2462110A1 (en) 2003-04-10
NO2014011I2 (no) 2015-08-31
AU2002333220B2 (en) 2008-02-07
PL368442A1 (pl) 2005-03-21
KR100783346B1 (ko) 2007-12-07
ME00039B (me) 2010-06-10
US9708280B2 (en) 2017-07-18
BR122012009534B8 (pt) 2019-01-29
HRP20040220A2 (en) 2005-02-28
ATE441631T1 (de) 2009-09-15
CY1107924T1 (el) 2013-09-04
JP3955614B2 (ja) 2007-08-08
AU2002333220A2 (en) 2003-04-14
BRPI0212733B8 (pt) 2021-05-25
PT1436271E (pt) 2008-04-10
JP3896116B2 (ja) 2007-03-22
JP2005505585A (ja) 2005-02-24
ZA200401583B (en) 2005-05-25
FR14C0033I2 (fr) 2014-11-14
US8110567B2 (en) 2012-02-07
US7144884B2 (en) 2006-12-05
MEP6508A (xx) 2010-02-10
US20050014740A1 (en) 2005-01-20
LTC1436271I2 (lt) 2016-09-12
HUS1400012I1 (hu) 2020-12-28
US20120302553A1 (en) 2012-11-29
NO326443B1 (no) 2008-12-08
US20060089368A1 (en) 2006-04-27
PL210551B1 (pl) 2012-02-29
US9090575B2 (en) 2015-07-28
AR066460A2 (es) 2009-08-19
KR20040047886A (ko) 2004-06-05
BE2014C036I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-11-22
DE60225162T2 (de) 2009-02-12
EA011096B1 (ru) 2008-12-30
RS27704A (en) 2006-10-27
HU230189B1 (hu) 2015-09-28
CA2462110E (en) 2003-04-10
EP1436271A1 (en) 2004-07-14
BR122012023120B1 (pt) 2017-03-21
US20180127389A1 (en) 2018-05-10
HUP0402313A3 (en) 2010-03-29
US7148238B2 (en) 2006-12-12
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
EA007537B3 (ru) 2015-02-27
NO20083446L (no) 2004-04-21
AU2006215994A1 (en) 2006-10-05
HK1072600A1 (zh) 2005-09-02
JP2007051149A (ja) 2007-03-01
CA2462110C (en) 2010-05-11
BR122012009534B1 (pt) 2018-02-27
IS2732B (is) 2011-04-15
EA007537B1 (ru) 2006-10-27
BR0212733B1 (pt) 2014-05-13
KR20070103515A (ko) 2007-10-23
NL300652I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-01-18
CN1561336A (zh) 2005-01-05
NO20041628L (no) 2004-04-21
IS2578B (is) 2010-02-15
DK1749818T3 (da) 2009-10-12
AU2002333220C1 (en) 2023-10-05
ATE386730T1 (de) 2008-03-15
EA200400498A1 (ru) 2004-08-26
CY2014022I2 (el) 2015-12-09
EP1749818A3 (en) 2008-04-02
IS7164A (is) 2004-02-26
MY140950A (en) 2010-02-12
JP3955613B2 (ja) 2007-08-08
IL160655A0 (en) 2004-07-25
JP2007031447A (ja) 2007-02-08
US7138407B2 (en) 2006-11-21
IS8806A (is) 2009-03-10
EP1749818B1 (en) 2009-09-02
US20070060574A1 (en) 2007-03-15
RS20120158A2 (en) 2012-10-31
HUP0402313A2 (hu) 2005-02-28
CY1110064T1 (el) 2015-01-14
KR100842702B1 (ko) 2008-07-01
EP1436271B1 (en) 2008-02-20
BR122012023120B8 (pt) 2022-01-18
ES2298425T3 (es) 2008-05-16
EP1749818A2 (en) 2007-02-07
US20060084662A1 (en) 2006-04-20
AU2006215994B2 (en) 2008-11-13
LTPA2014013I1 (lt) 2014-04-25
US20140163043A1 (en) 2014-06-12
LU92397I2 (fr) 2014-05-12
DE60225162D1 (de) 2008-04-03
US7683053B2 (en) 2010-03-23
FR14C0033I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-06-13
WO2003029232A1 (en) 2003-04-10
UA93857C2 (uk) 2011-03-25
EP1436271B3 (en) 2022-04-20
PL209253B1 (pl) 2011-08-31
US20210276966A1 (en) 2021-09-09
CN1319958C (zh) 2007-06-06
SI1436271T1 (sl) 2008-06-30
EA200601269A1 (ru) 2007-02-27
DK1436271T6 (da) 2022-06-27
MXPA04002959A (es) 2004-07-05
AR036659A1 (es) 2004-09-22

Similar Documents

Publication Publication Date Title
HU228956B1 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
DK175839B1 (da) Forbindelser af typen 6H-benzfuro[3a,3,-ef][2]benzazepin samt anvendelse af disse til behandling af Alzheimer's syge
RU2409365C2 (ru) ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА ДЛЯ ЛЕЧЕНИЯ СИМПТОМОВ БОЛЕЗНИ ГЕНТИНГТОНА
ES2367532T3 (es) Derivados de imidazolidina, sus usos, su preparación y composicones que los contienen.
EP2813498B1 (en) Compounds for Alzheimer's disease
CN105481796B (zh) 一类氨基甲酸查尔酮酯类化合物、其制备方法和用途
WO2011050962A1 (en) Acid addition salts of lenalidomide
ES2609264T3 (es) Formas sólidas que comprenden (-)-O-desmetilvenlafaxina y usos de las mismas
CN100591660C (zh) 非甾体雄激素受体调节剂及其制备方法、药物组合物和用途
HUE030848T2 (hu) Benzilidén-guanidin-származékok és terápiás alkalmazásuk fehérjék hibás feltekeredésével összefüggõ betegségek kezelésében
US11420950B2 (en) Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
JPH02290841A (ja) 新規化合物、その製法及びそれを含む医薬組成物
CN108069942A (zh) 苯酞吡唑酮类偶联物、其制备方法和用途
MX2011006791A (es) Compuestos de metodos para el tratamiento de dolor y otras enfermedades.
TW200808784A (en) Substituted phenyl methanone derivatives
CN102807575A (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
CN101092414A (zh) 一类6－芳基－3－环氨基甲基吡喃酮类衍生物的制备及用途
AU2005257768A1 (en) Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
TW205546B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP1828125B1 (fr) Derives d'arylpiperazine et leur utilisation comme ligands selectifs du recepteur d3 de la dopamine
Rose et al. Practical synthesis of capromorelin, a growth hormone secretagogue, via a crystallization-induced dynamic resolution
RU2716814C2 (ru) Новые производные азетидина, полезные в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии
CN106632191B (zh) 高异黄酮曼尼希碱类化合物、其制备方法和用途
KR20110074574A (ko) 1-부틸-2-히드록시아르알킬 피페라진 유도체 및 항-우울증제로서의 그 용도
TW200916092A (en) N-oxides of venlafaxine and O-desmethylvenlafaxine as prodrugs

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: VORTIOXETINE (BRINTELLIX); REG. NO/DATE: EU/1/13/891 20131218

Spc suppl protection certif: S1400012

Filing date: 20140312

Expiry date: 20221002

FG4S Grant of supplementary protection certificate

Spc suppl protection certif: S1400012

Filing date: 20140312

Expiry date: 20221002

Extension date: 20271002